Table 1. Available medication for the treatment of hepatitis C virus infection.
| Drugs regimens | HCV genotype indication | Use in Pregnancy |
|---|---|---|
| Interferon: | ||
| (1)PegInterferon- alfa-2a ± (2)Ribavirin* | Genotype 1-6 | (1)C, (2)X |
| (1)PegInterferon- alfa-2b ± (2)Ribavirin* | Genotype 1-6 | (1)C, (2)X |
|
Directly acting antivirals: DAA† + PEG interferon combination: (1)Boceprevir+(2)Peginterferon (1)Telaprevir+(2)PEG Interferon (1)Simeprevirα+ (2)PEG interferon (1) Sofosbuvirα+ (2)PEG interferon |
Genotype 1 Genotype 1 Genotype 1 Genotype 1 & 4 |
(1), (2)C (1)N/A, (2)C (1)C, (2)C (1)B, (2)C |
|
DAA only: SOF containing regimens |
||
|
(1)Sofosbuvirα ± (2)Ribavirin* (1)Sofosbuvirα + (2)Simeprevirα (1)Sofosbuvirα + (2)Ledipasvirα (1)Sofosbuvirα + (2)Daclatasvir (1)Sofosbuvirα + (2)Velpataspavirα (1)Sofosbuvirα + (2)velpatasvirα + (3)voxilaprevirα |
Genotype 2 & 3 Genotype 1 Genotype 1, 4, 5, & 6 Genotype 1-6 Genotype 1-6 Genotype 1-6 |
(1)B, (2)X (1)B, (2)C (1)B, (2)B (1)B, (2)N/A‡ (1)B, (2)N/A (1)B, (2)N/A, (3)N/A |
|
Non-SOF agents (1)Ombitasvirα + (2)Paritaprevirα + (3)ritonavirα + (4)dasabuvirα (1)Ombitasvirα + (2)Paritaprevirα + (3)ritonavirα (1)Elbasvirα + (2)grazoprevirα (1)Glecaprevirα + (2)Pibrentasvirα (1)Daclatasvir + (2)asunaprevir |
Genotype 1 Genotype 4 Genotype 1 Genotype 1-6 Genotype 1 with renal impairment |
(1)B, (2)B, (3)N/A, (4)B (1)B, (2)B,(3)N/A (1)N/A, (2)N/A (1)N/A, (2)N/A (1)N/A, (2)N/A |
Ribavirin is contraindicated due to its teratogenicity (FDA recommendation: X in pregnancy) and removed in other regimens which are given with/without ribavirin.
αFDA approved
Not available.